258 related articles for article (PubMed ID: 28946903)
21. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
22. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
24. Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation.
Xu J; Zhang Z; Qian M; Wang S; Qiu W; Chen Z; Sun Z; Xiong Y; Wang C; Sun X; Zhao R; Xue H; Li G
J Exp Clin Cancer Res; 2020 Apr; 39(1):59. PubMed ID: 32252802
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop.
Jiang L; Lin C; Song L; Wu J; Chen B; Ying Z; Fang L; Yan X; He M; Li J; Li M
J Clin Invest; 2012 Jan; 122(1):33-47. PubMed ID: 22156201
[TBL] [Abstract][Full Text] [Related]
26. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
27. Jagged1 is Clinically Prognostic and Promotes Invasion of Glioma-Initiating Cells by Activating NF-κB(p65) Signaling.
Hai L; Liu P; Yu S; Yi L; Tao Z; Zhang C; Abeysekera IR; Li T; Tong L; Ma H; Liu B; Xie Y; Zhou X; Lin Y; Zhu M; Zhang K; Ren B; Ming H; Huang Y; Yang X
Cell Physiol Biochem; 2018; 51(6):2925-2937. PubMed ID: 30580328
[TBL] [Abstract][Full Text] [Related]
28. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
[TBL] [Abstract][Full Text] [Related]
29. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
30. Netrin-1 promotes glioma growth by activating NF-κB via UNC5A.
Chen JY; He XX; Ma C; Wu XM; Wan XL; Xing ZK; Pei QQ; Dong XP; Liu DX; Xiong WC; Zhu XJ
Sci Rep; 2017 Jul; 7(1):5454. PubMed ID: 28710382
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
[TBL] [Abstract][Full Text] [Related]
32. Inhibitor of Bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages.
Fan Z; Wang Y; Xu X; Wu Y
Int Immunopharmacol; 2018 May; 58():145-153. PubMed ID: 29587203
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
34. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
35. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
36. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Liu L; Shi B; Wang X; Xiang H
Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
[TBL] [Abstract][Full Text] [Related]
37. The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells.
Tai PA; Liu YL; Wen YT; Lin CM; Huynh TT; Hsiao M; Wu ATH; Wei L
Mol Imaging; 2019; 18():1536012119870899. PubMed ID: 31478435
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
39. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
40. The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway.
Liu S; Zheng M; Li Y; He L; Chen T
Psychopharmacology (Berl); 2020 Feb; 237(2):465-477. PubMed ID: 31811349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
